Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
7 hedge funds and large institutions have $2.13M invested in Loncar China BioPharma ETF in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
13% more capital invested
Capital invested by funds: $1.9M → $2.13M (+$240K)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$325K |
| 2 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
+$15.9K |
| 3 |
WEC
Winslow Evans & Crocker
Boston,
Massachusetts
|
+$14.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$223K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$15.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $1.35M | -$223K | -7,275 | -15% |
|
|
2
Citadel Advisors
Miami,
Florida
| $346K | +$325K | +10,621 | New |
|
|
FEM
3
Fulcrum Equity Management
Plano,
Texas
| $326K | +$15.9K | +519 | +5% |
|
4
Morgan Stanley
New York
| $65K | – | – | – |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| $23K | +$1.07K | +35 | +5% |
|
|
WEC
6
Winslow Evans & Crocker
Boston,
Massachusetts
| $15K | +$14.4K | +470 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $13K | -$15.1K | -494 | -56% |
|
CHNA Hedge Fund Activity: Q4 2020 in Review
7 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q4 2020, worth a combined $2.13M — up 13% from $1.9M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CHNA positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $325K. The largest seller was Jane Street, cutting an estimated $223K.
- 7 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q4 2020, up from 6 in Q3 2020.
- Funds reported $2.13M of Loncar China BioPharma ETF stock for Q4 2020, up 13% quarter-over-quarter.
- 2 funds opened new Loncar China BioPharma ETF positions in Q4 2020 and 1 closed out, a net change of +1 holder.
- The largest Loncar China BioPharma ETF buyer in Q4 2020 was Citadel Advisors, an estimated $325K added.
- The largest Loncar China BioPharma ETF seller in Q4 2020 was Jane Street, an estimated $223K sold.
Based on aggregated 13F filings for Q4 2020.